Vericel (NASDAQ:VCEL) Director Robert Md Zerbe Sells 3,000 Shares of Company Stock

Posted by Brenda Bartman on Nov 7th, 2026

Vericel Corporation (NASDAQ:VCEL – Get Free Report) Director Robert Md Zerbe sold 3,000 shares of the firm’s stock in a transaction on Thursday, November 5th. The shares were sold at an average price of $52.23, for a total transaction of $156,690.00. Following the transaction, the director directly owned 32,995 shares of the company’s stock, valued at $1,723,328.85. The trade was a 8.33% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Vericel Price Performance

Shares of Vericel stock traded up $2.84 during trading on Friday, hitting $54.62. The company’s stock had a trading volume of 1,612,332 shares, compared to its average volume of 564,100. The stock has a market cap of $2.80 billion, a price-to-earnings ratio of 85.35 and a beta of 1.08. Vericel Corporation has a 52 week low of $28.95 and a 52 week high of $55.60. The stock has a 50-day moving average price of $41.01 and a two-hundred day moving average price of $38.90.

Vericel (NASDAQ:VCEL – Get Free Report) last released its earnings results on Thursday, November 5th. The biotechnology company reported $0.27 earnings per share for the quarter, beating analysts’ consensus estimates of $0.06 by $0.21. Vericel had a net margin of 7.91% and a return on equity of 6.91%. The business had revenue of $85.37 million during the quarter, compared to the consensus estimate of $77.95 million. During the same quarter in the prior year, the firm posted $0.10 EPS. The company’s revenue for the quarter was up 26.5% compared to the same quarter last year. On average, equities analysts predict that Vericel Corporation will post 0.54 EPS for the current fiscal year.

Key Headlines Impacting Vericel

Here are the key news stories impacting Vericel this week:

Positive Sentiment: Vericel reported Q3 revenue of $85.4 million, up 26.5% year over year and above the $78.0 million consensus. Earnings per share of $0.27 also topped estimates of $0.06, while net income rose 179% to $14.2 million. Vericel Q3 results and guidance
Positive Sentiment: The company raised its FY2026 revenue outlook to $344 million–$346 million, above analyst expectations of roughly $336 million, and lifted its adjusted EBITDA margin guidance to 28%. The stronger outlook, alongside record MACI sales, helped fuel investor optimism. Vericel shares rise on record revenue and higher outlook
Positive Sentiment: HC Wainwright raised its price target to $75 from $72 and maintained a Buy rating, signaling continued analyst confidence in the stock’s prospects. HC Wainwright price target update
Negative Sentiment: Several Vericel directors and insiders disclosed stock sales totaling about 22,000 shares on November 4–5. One insider’s sale reduced their reported stake by 88%, which may be a near-term concern for investors, though insider sales alone do not establish a negative outlook. SEC insider transaction filing

Hedge Funds Weigh In On Vericel

A number of hedge funds and other institutional investors have recently made changes to their positions in VCEL. MCF Advisors LLC boosted its stake in Vericel by 293.0% in the 2nd quarter. MCF Advisors LLC now owns 782 shares of the biotechnology company’s stock worth $35,000 after purchasing an additional 583 shares during the period. Ameritas Advisory Services LLC purchased a new stake in Vericel in the 2nd quarter worth approximately $36,000. Allworth Financial LP purchased a new stake in Vericel in the 2nd quarter worth approximately $60,000. Integrated Wealth Concepts LLC bought a new position in Vericel in the 2nd quarter valued at $72,000. Finally, GAMMA Investing LLC boosted its holdings in Vericel by 17.7% in the 2nd quarter. GAMMA Investing LLC now owns 1,886 shares of the biotechnology company’s stock valued at $84,000 after purchasing an additional 283 shares during the period.

Analyst Ratings Changes

VCEL has been the topic of a number of research reports. Truist Financial set a $65.00 price target on Vericel in a research note on Friday. Wall Street Zen raised shares of Vericel from a “buy” rating to a “strong-buy” rating in a research report on Saturday. HC Wainwright boosted their price objective on Vericel from $72.00 to $75.00 and gave the stock a “buy” rating in a report on Friday. TD Cowen increased their price objective on Vericel from $55.00 to $58.00 and gave the stock a “buy” rating in a research note on Friday, July 31st. Finally, Canaccord Genuity Group set a $60.00 target price on Vericel in a report on Thursday, July 30th. Four equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $60.80.

Read Our Latest Stock Analysis on Vericel

Vericel Company Profile

(Get Free Report)

Vericel Corporation is a commercial-stage biopharmaceutical company focused on developing and marketing advanced cell therapies and regenerative medicine products. The company serves orthopedic and burn-care markets, with an emphasis on treatments that use a patient’s own cells or biologic materials to support tissue repair and healing.

Vericel’s primary orthopedic product is MACI, an autologous cultured chondrocyte implant used to repair symptomatic cartilage defects of the knee in adults.